Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Forest returns desmoteplase rights to Paion

FRX terminated a 2004 deal under which Paion (FSE:PA8) granted FRX exclusive

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE